Phase I study of combination drug purging for autologous bone marrow transplantation

Scott D. Rowley, Carole B. Miller, Steven Piantadosi, Janice M. Davis, George W. Santos, Richard J. Jones

Research output: Contribution to journalArticle

Abstract

In a phase I clinical trial of autologous bone marrow transplantation, we determined the feasibility of ex vivo purging with high concentrations of pharmacologics in combination. Light-density cells isolated from the grafts of 26 patients with acute leukemia or lymphoblastic lymphoma were treated with 4-hydroperoxycyclophosphamide (4-HC; 30 to 60 μg/mL), vincristine (Vcr; 1.5 to 3.0 μg/mL), and methylprednisolone sodium succinate (MP; 5 mg/mL). All patients received marrow-lethal induction therapy followed by infusion of the treated grafts. Three patients died of transplantrelated complications before achieving peripheral blood recovery of greater than 0.5 × 109 granulocytes per liter. All other patients achieved this parameter of engraftment at a median of 35 days after marrow infusion. The median time to last platelet transfusion was 45 days. These durations of aplasia were similar to those experienced by other patients receiving density-gradient separated grafts treated with 60 ×g/mL of 4-HC as a single agent. No patient required infusion of untreated reserve marrow because of engraftment failure. The colony-forming unit-granulocyte macrophage (CFU-GM) content of the grafts after purging predicted these parameters of engraftment. Colony-forming unit - leukemia (CFU-L) cultured from the grafts of 12 of the patients treated for acute lymphoblastic leukemia (ALL) were considerably more sensitive to the combination regimen than to 4-HC alone; the sensitivity of CFU-GM from these patients did not differ between the two regimens. The results of this trial indicate the feasibility of treating autologous bone marrow grafts with high concentrations of pharmacologies in combination. The use of combinations may increase the efficacy of ex vivo purging without increasing the toxicity to normal hematopoietic cells.

Original languageEnglish (US)
Pages (from-to)2210-2218
Number of pages9
JournalJournal of Clinical Oncology
Volume9
Issue number12
DOIs
StatePublished - Dec 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I study of combination drug purging for autologous bone marrow transplantation'. Together they form a unique fingerprint.

  • Cite this